文献速递膀胱癌与上尿路尿路上皮癌

NIMBUS试验:减少BCG灌注次数在高危非肌层浸润性膀胱癌中劣于标准方案

Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".
PubMed 文献 · Eur Urol · 2020-05-20

NIMBUS是一项随机III期试验,纳入345例高危非肌层浸润性膀胱癌患者,比较减少次数的标准剂量BCG灌注(9次)与标准次数和剂量(15次)的疗效。中位随访12个月,意向性分析显示减少次数组复发46/170例,标准组21/175例,风险比0.40(单侧97.5%CI上限0.68),达到预设劣效停止标准,试验提前终止。结论:减少BCG灌注次数在首次复发时间上劣于标准方案。

要点

  • 减少BCG灌注次数(9次 vs 15次)显著增加高危NMIBC复发风险,试验因劣效提前终止。
  • 标准剂量BCG的完整灌注次数(诱导6周+维持9周)仍是高危NMIBC的标准治疗。
  • 临床不应以减少灌注次数来降低BCG毒性,需探索其他减毒策略。

核心结论

  • 减少BCG灌注次数方案在首次复发时间上劣于标准次数和剂量方案,试验提前终止以避免减少次数组受害。

研究设计与样本

  • 欧洲泌尿外科学会研究基金会随机III期临床试验NIMBUS,2013年12月至2019年7月从51个中心随机345例高危NMIBC患者。
  • 减少次数组170例,标准组175例;中位随访12个月,意向性分析。

主要发现

  • 减少次数组复发46/170例,标准组复发21/175例。
  • 风险比0.40,单侧97.5%置信区间上限0.68,达到预设劣效停止标准。
  • 初始电切时预后因素:Ta/T1为46%/54%,原发/复发为92%/8%,单发/多发为57%/43%,合并原位癌27%。

关键数值与推荐

  • 标准BCG方案:6周诱导后,在第3、6、12个月各进行3周维持灌注,共15次。
  • 减少次数BCG方案:第1、2、6周诱导,第3、6、12个月各进行2周(第1、3周)维持,共9次。
  • 主要终点为首次复发时间,次要终点包括进展至≥T2和毒性。
  • 预设劣效停止标准:风险比单侧97.5%置信区间上限超过预设值(具体阈值未在摘要中报告)。

临床怎么用

  • 高危NMIBC患者应接受标准次数和标准剂量的BCG灌注,不应以减少灌注次数来降低毒性。
  • 完整的肿瘤切除和标准BCG灌注次数仍是当前标准治疗。

局限性

  • 报告基于2019年7月1日截止日期后的数据审查和安全分析,中位随访仅12个月。
  • 试验因劣效提前终止,长期肿瘤学结局未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravesical instillation of bacillus Calmette-Guérin (BCG) is an accepted strategy to prevent recurrence of non-muscle-invasive bladder cancer (NMIBC) but associated with significant toxicity. OBJECTIVE: NIMBUS assessed whether a reduced number of standard-dose BCG instillations are noninferior to the standard number and dose in patients with high-grade NMIBC. DESIGN, SETTING, AND PARTICIPANTS: A total of 345 patients from 51 sites were randomised between December 2013 and July 2019. We report results after a data review and safety analysis by the Independent Data Monitoring Committee based on the cut-off date of July 1, 2019. INTERVENTION: The standard BCG schedule was 6 wk of induction followed by 3 wk of maintenance at 3, 6, and 12 mo (15 instillations). The reduced frequency BCG schedule was induction at wks 1, 2, and 6 followed by 2 wk (wks 1 and 3) of maintenance at 3, 6, and 12 mo (nine instillations). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was time to first recurrence. Secondary endpoints included progression to ≥ T2 and toxicity. RESULTS AND LIMITATIONS: In total, 170 patients were randomised to reduced frequency and 175 to standard BCG. Prognostic factors at initial resection were as follows: Ta/T1: 46/54%; primary/recurrent: 92/8%; single/multiple: 57/43%; and concomitant carcinoma in situ: 27%. After 12 mo of median follow-up, the intention-to-treat analysis showed a safety-relevant difference in recurrences between treatment arms: 46/170 (reduced frequency) versus 21/175 patients (standard). Additional safety analyses showed a hazard ratio of 0.40 with the upper part of the one-sided 97.5% confidence interval of 0.68, meeting a predefined stopping criterion for inferiority. CONCLUSIONS: The reduced frequency schedule was inferior to the standard schedule regarding the time to first recurrence. Further recruitment of patients was stopped immediately to avoid harm in the reduced frequency BCG arm. PATIENT SUMMARY: After surgical removal of the tumour, patients with high-grade non-muscle-invasive bladder cancer are treated with bacillus Calmette-Guérin to prevent recurrence and progression. This is associated with significant side effects. We report the results of a clinical trial showing a reduction in the number of instillations (from 15 to nine in total) being inferior to the standard protocol. From today's perspective, complete tumour resection and a standard number of instillations remain the standard of care.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Grimm MO, van der Heijden AG, Colombel M, et al. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". Eur Urol. 2020. PMID: 32446864. doi:10.1016/j.eururo.2020.04.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。